REGEnLIFE at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

REGEnLIFE takes part in 2 sessions at CTAD 2026 in Boston. Its program centres on brain and gut photobiomodulation for mild to moderate Alzheimer's disease. Its work covers progress in the Light4Life pivotal trial and a next-generation home-based version of the therapy.

OrganizationCTAD 2026 Attendance
REGEnLIFE
Paris, France
regenlife.com
Biotech
Makes the RGn, a photobiomodulation device worn on the head and abdomen, tested in the Light4Life pivotal trial in Alzheimer's disease.
Poster
Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue
Poster

Explore the full CTAD 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Boston. Leave your work email and we’ll be in touch.

Privacy

Download the full CTAD 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from REGEnLIFE

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction